Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

TIKOSYN 500 MCG CAPSULE

dofetilide
$10.7711per EA
High Outlier

Strength

.5 mg/1

Manufacturer

Pfizer Inc.

NDC

00069582060

Classification

Brand

Dosage Form

CAPSULE

Route

ORAL

Last Updated

1/1/2025

Active Ingredients

DOFETILIDE

Approval Type

New Drug (NDA)

FDA Application

NDA020931

On Market Since

10/1/1999

Pharmacological Classes

Antiarrhythmic

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

0.0%

3Y

+2.0%

5Y

+7.2%

All

+160.6%

Generic Alternatives

1 alternative • Same active ingredient

TIKOSYN 500 MCG CAPSULE
Brand
00069582061•Pfizer Inc.
$10.7711

Related Drugs

Same classification

XYLOCAINE 2%-EPI 1:100,000
Brand
63323048327•Fresenius Kabi USA, LLC
$0.2655
per ML
XYLOCAINE 1%-EPI 1:100,000
Brand
63323048226•Fresenius Kabi USA, LLC
$0.2721
per ML
XYLOCAINE 1%-EPI 1:100,000
Brand
63323048227•Fresenius Kabi USA, LLC
$0.2721
per ML
SOTYLIZE 5 MG/ML ORAL SOLUTION
Brand
24338053025•Azurity Pharmaceuticals Inc.
$2.3056
per ML
SOTYLIZE 5 MG/ML ORAL SOLUTION
Brand
24338053048•Azurity Pharmaceuticals Inc.
$2.3353
per ML
NORPACE CR 100 MG CAPSULE
Brand
00025273231•Pfizer Inc.
$4.1412
per EA
NORPACE CR 150 MG CAPSULE
Brand
00025274231•Pfizer Inc.
$4.9062
per EA
ZTLIDO 1.8% TOPICAL SYSTEM
Brand
69557011130•Scilex Pharmaceuticals Inc.
$12.3221
per EA
MULTAQ 400 MG TABLET
Brand
00024414260•Sanofi-Aventis U.S. LLC
$13.1941
per EA
NUEDEXTA 20-10 MG CAPSULE
Brand
59148005316•Otsuka America Pharmaceutical Inc.
$26.6488
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy